8-K: NeuroPace Refocuses on Core RNS System, Ends SEEG Distribution Deal with DIXI Medical

NeuroPace is strategically refocusing on its RNS System, leading to the termination of its distribution agreement with DIXI Medical for SEEG products, while reaffirming its 2025 revenue guidance and long-term financial goals.

Summary

• NeuroPace is strategically refocusing its product portfolio on its core RNS System.
• The company is terminating its distribution agreement with DIXI Medical for Stereo EEG (SEEG) products, with the wind-down occurring in Q4 2025 and Q1 2026.
• NeuroPace is maintaining its 2025 revenue guidance.
• The company expects to achieve cash flow breakeven by the end of 2027 and maintain a 20%+ revenue CAGR.
• The decision to end the DIXI Medical agreement was made because NeuroPace's core growth strategy has evolved.
• The company will focus on clinical, product, and market development initiatives around RNS therapy, including Project CARE and indication expansion.
• NeuroPace believes focusing on the RNS System will lead to more efficient and faster development and execution of opportunities.
• The company will continue selling remaining DIXI product inventory during the six-month period following the agreement's expiration on September 30, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the termination of the DIXI Medical agreement is a negative, the company is maintaining its revenue guidance and expects to see long-term benefits from focusing on its core RNS System. The high gross margin on the RNS System and the potential for future growth are also positive factors.

Positives

• NeuroPace is maintaining its 2025 revenue guidance despite ending the DIXI Medical distribution agreement.
• The company expects to achieve cash flow breakeven by the end of 2027 and maintain a 20%+ revenue CAGR.
• NeuroPace's gross margin is expected to increase as the margin for SEEG distributed products is approximately 50%, while the margin of the RNS System is over 78%.
• The company anticipates significant growth opportunities in 2026, including Project CARE expansion and indication expansion into new patient populations.

Negatives

• NeuroPace is terminating its distribution agreement with DIXI Medical for SEEG products, which will result in the loss of revenue from SEEG product sales.
• The wind-down of the DIXI Medical agreement will occur in Q4 2025 and Q1 2026, potentially impacting revenue during that period.

Risks

• Actual operating results may differ significantly from any guidance provided.
• There are uncertainties related to market acceptance and adoption of NeuroPace's RNS System.
• NeuroPace could use its cash resources sooner than expected and may not be able to achieve cash flow breakeven on the anticipated timeline or at all.
• NeuroPace's gross margin for its RNS System may be lower than forecast.
• There are risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for NeuroPace's RNS System.
• There are risks related to product development, including risks related to the development of AI-powered software.
• NeuroPace may not be able to meet its long-range plans and revenue projections without DIXI Medical revenue as a result of the planned expiration of the distribution agreement.

Future Outlook

NeuroPace anticipates significant growth opportunities in 2026, including the ongoing expansion of Project CARE, indication expansion into the drug-resistant idiopathic generalized epilepsy population, and the launch of AI-enabled software products. The company expects to achieve cash flow breakeven by the end of 2027 and maintain a 20%+ revenue CAGR.

Management Comments

• Joel Becker, NeuroPace Chief Executive Officer, stated that the decision to end the DIXI Medical agreement was made because NeuroPace's core growth strategy has evolved.
• Becker believes that focusing on the RNS System will lead to more efficient and faster development and execution of opportunities.
• Becker is confident that this will lead to more efficient, effective and faster development and execution of our opportunities and establish NeuroPace and the RNS System as the clear leader in the field.

Industry Context

NeuroPace's decision to focus on its core RNS System reflects a trend in the medical device industry towards specialization and focusing on differentiated products. The company's exit from the SEEG distribution agreement suggests that it sees greater potential in its own proprietary technology.

Comparison to Industry Standards

• The RNS System is unique as a brain-responsive neurostimulation system, setting it apart from competitors in the epilepsy treatment market.
• Companies like Medtronic and LivaNova offer vagus nerve stimulation (VNS) therapy for epilepsy, which is a different approach than NeuroPace's RNS System.
• Other companies in the epilepsy monitoring space include those offering EEG monitoring systems, but these do not provide the closed-loop therapeutic intervention of the RNS System.
• The 78%+ gross margin on the RNS System is strong compared to typical medical device margins, suggesting a premium product with significant value.

Stakeholder Impact

• Shareholders may see long-term benefits from the company's strategic refocusing on its core RNS System.
• Customers (patients with epilepsy) may benefit from the company's focus on developing and improving the RNS System.
• Employees may be affected by the wind-down of the DIXI Medical agreement, but the company expects to see growth in other areas.
• DIXI Medical will be impacted by the termination of the distribution agreement.

Next Steps

• NeuroPace will wind down its distribution relationship with DIXI Medical in Q4 2025 and Q1 2026.
• The company will focus on clinical, product, and market development initiatives around RNS therapy, including Project CARE and indication expansion.
• NeuroPace plans to launch AI-enabled software products.
• The company will continue selling remaining DIXI product inventory during the six-month period following the agreement's expiration.

Key Dates

Keywords

NeuroPace, RNS System, epilepsy, SEEG, DIXI Medical, distribution agreement, revenue guidance, cash flow breakeven, medical device, Project CARE